The tumor mutation burden (median 0.28, range: 0–4.76) in our TFE3-tRCC cohort was lower than that of KIRC and KIRP in TCGA cohort (Supplementary Figure 5). This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.